Zug, Switzerland and Paris (ots/PRNewswire) - Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, ...
Lausanne, Switzerland (ots/PRNewswire) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a ...
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
Parma, Italy, and Cleveland, Ohio (ots/PRNewswire) - - New investment will progress treatment of pulmonary arterial hypertension (PAH), a rare condition which causes high blood pressure in the blood vessels that supply the lungs and can lead to heart failure. - Current approved medications mainly address the ...
Petah Tikva, Israel (ots/PRNewswire) - New Clinical Data Supports Use of Biobeat ABPM Cuffless-Monitor as Reliable and Accurate Solution for Out-of-Clinic Blood Pressure Monitoring Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, announced today the launch of its new wearable and continuous ambulatory blood pressure ...
Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...
Not intended for US, Canada and UK-based media Darmstadt, Germany, and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the ...
Not intended for distribution in the USA, Canada or the UK Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: 4062; 4934. - New subgroup analyses for ...
Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Darmstadt, Germany and ...
- Data presentations from ENTRUST-AF PCI and ETNA-AF add to the growing body of scientific evidence from the Edoxaban Clinical Research Programme - First-time presentation of ENTRUST-AF PCI clincial results assessing edoxaban in atrial fibrillation (AF) patients following a successful percutaneous coronary ...
- Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver - Bempedoic acid significantly reduced LDL-Cholesterol (LDL-C) vs placebo at week 12 (primary endpoint, absolute reduction -36mg/dL, -21,4%) - Over 24-weeks, bempedoic acid was ...
Munich (ots/PRNewswire) - - In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA® (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented - EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural ...
- Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 CLEAR Wisdom at the American College of Cardiology (ACC) 2019 Scientific Sessions - Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated and Adverse Event Profile was Similar to that of Placebo[1] - Bempedoic Acid is an ...
Munich (ots/PRNewswire) - - ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice - Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm ...
Munich and Ann Arbor, Michigan (ots/PRNewswire) - - Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces ...
Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...
Munich (ots/PRNewswire) - - Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis ...
Bagsværd, Denmark (ots/PRNewswire) - - Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] - Despite the high incidence, 1 in 4 people with type 2 diabetes have never discussed, or cannot recall discussing, CVD risk factors with a doctor[2] - First-ever global ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...
Munich (ots/PRNewswire) - - Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE - This analysis provides benefit/risk assessment in different types of ...